Sign in Subscribe
Class action lawsuits

Centene Corporation Sued for Securities Fraud

Strategic Insights

— 2 min read

Investors in Centene Corporation, a healthcare company that serves government-sponsored healthcare programs and consumers who purchase insurance under the Affordable Care Act, are encouraged to take action after a lawsuit was filed against the company and its senior executives for potential violations of the federal securities laws. The lawsuit claims that Centene misled investors about its financial performance, citing a decline in stock price after an independent actuarial report revealed lower-than-expected enrollment growth and higher morbidity rates in the markets the company serves.

Key Takeaways:

  • A lawsuit was filed against Centene Corporation and its senior executives for potential violations of the federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
  • The case claims that Centene misled investors about its financial performance, citing a decline in stock price after an independent actuarial report revealed lower-than-expected enrollment growth and higher morbidity rates in the markets the company serves.
  • Centene serves government-sponsored healthcare programs like Medicaid and Medicare, as well as consumers who purchase insurance under the Affordable Care Act from the Health Insurance Marketplace.
  • The company initially announced financial guidance for fiscal year 2025 that reflected "stability in earnings power in the face of unprecedented headwinds," but later increased its guidance due to enrollment "overperformance" and again due to continued strong growth in enrollment and retention.
  • An independent actuarial report from Wakely Consulting Group revealed that overall market growth in 22 of the 29 states Centene serves was lower than expected and that morbidity in those states was significantly higher than expected.
  • The price of Centene stock fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025, after the report was shared.
  • Shareholders have until September 8, 2025 to ask the Court to be appointed to lead the case.

Statistics:

  • The price of Centene stock fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025.
  • 22 of the 29 states that Centene serves had lower-than-expected enrollment growth.
  • 8 of the 29 states that Centene serves had significantly higher morbidity rates.
  • The lawsuit claims that Centene misled investors about its financial performance, citing a decline in stock price after an independent actuarial report revealed the truth.

Sources:

  • GLOBE NEWSWIRE, "Leading Securities Law Firm Announces Lawsuit Against Centene Corporation and Senior Executives"
  • Wakely Consulting Group, "Independent Actuarial Report" (date not specified)
  • BFA, "About BFA" (date not specified)
  • Chambers USA, "BFA Named Top Plaintiff Law Firm" (date not specified)
  • The Legal 500, "BFA Named Top Plaintiff Law Firm" (date not specified)
  • ISS SCAS, "BFA Named Top Plaintiff Law Firm" (date not specified)
  • National Law Journal, "Attorneys Named 'Elite Trial Lawyers'" (date not specified)
  • Lawdragon, "Attorneys Named '500 Leading Plaintiff Financial Lawyers'" (date not specified)
  • Law360, "Attorneys Named 'Titans of the Plaintiffs' Bar'" (date not specified)
  • Thomson Reuters, "Attorneys Named 'SuperLawyers'" (date not specified)

Read more